Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Complement binding aptamers and anti-C5 agents useful in the treatment of ocular disorders

A complement and aptamer technology, applied in the field of nucleic acids, can solve problems such as toxicity and immunogenicity

Inactive Publication Date: 2009-05-27
ARCHEMIX CORP
View PDF43 Cites 9 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0011] 2) Toxicity and immunogenicity
[0021] While the complement system plays an important role in maintaining health, it also has the potential to cause or contribute to disease

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Complement binding aptamers and anti-C5 agents useful in the treatment of ocular disorders
  • Complement binding aptamers and anti-C5 agents useful in the treatment of ocular disorders
  • Complement binding aptamers and anti-C5 agents useful in the treatment of ocular disorders

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0717] Anti-C5 aptamer activity in the classical and alternative complement pathways

Embodiment 1A

[0718] Example 1A: Hemolysis Test

[0719] The CH50 assay tests the ability of the complement system to solubilize 50% of a standard suspension of antibody-coated sheep red blood cells in a serum test sample. 0.2% human serum was mixed with antibody-coated sheep erythrocytes (DiamedixEZ Complement CH50 Kit, Diamedix Corp, Miami, FL) in the presence or absence of various anti-C5 aptamers. Operated according to the kit protocol, in barbiturate-buffered saline solution containing calcium, magnesium and 1% gel (GVB ++ complement buffer) at 37°C for 30 minutes. After incubation, samples were centrifuged to pellet intact red blood cells. The absorbance (OD) of the suspension was measured at 412nm 412 ) to quantify soluble hemoglobin, which is proportional to the degree of hemolysis (Green et al. (1995) Chem. Biol. 2:683-95). To verify that the aptamer inhibited C5 activity, some hemolyzed supernatants were analyzed for the presence of C5a and C5b-9 by ELISA according to the pr...

Embodiment 1B

[0737] Example 1B: Whole blood assay.

[0738] The following whole blood assay was used to analyze the effect of anti-C5 aptamers on the selective pathways of the complement system. Blood was isolated from normal human volunteers in the absence of anticoagulants. Aliquots of blood (without anti-anticoagulant) were reacted with increasing concentrations of ARC186 (sequence number: 4) at room temperature or 37°C for 5 hours. The serum was separated from the samples by centrifugation, and the presence of C5b in the serum was determined by sC5b-9 ELISA (C5b-9 ELISA kit, Quidel, San Diego, CA). Such as Figure 15 As shown, the anti-complement activity represented by C5b-9 has a deviation of 3 μM between samples incubated at different temperatures. The room temperature data showed that the aptamer concentrations required for quantitative inhibition ranged from 3–6 μM, while the reported C5 concentration was approximately 400 nM. These results show that more than a 10-fold mola...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
molecular weightaaaaaaaaaa
molecular weightaaaaaaaaaa
molecular weightaaaaaaaaaa
Login to View More

Abstract

Methods of treating complement-mediated ocular disorders by administering agents that inhibit a subject's complement component in an amount sufficient to treat the ocular disorder wherein, in a selected embodiment, said agent is an anti-complement aptamer that, in a preferred embodiment, is an anti-C5 aptamer.

Description

[0001] related application [0002] This patent application claims priority to U.S. Provisional Patent Application Serial No. 60 / 780905, filed March 8, 2006, and U.S. Provisional Patent Application Serial No. 60 / 848274, filed September 29, 2006, which are incorporated by reference at This is incorporated herein in its entirety. field of invention [0003] The present invention relates generally to the field of nucleic acids, and more particularly to aptamers that can bind proteins of the complement system for use in complement-associated ocular, cardiac, inflammatory, asthmatic, and autoimmune disorders, ischemia-reperfusion injury and / or other C5-mediated Treatment and diagnosis of diseases or disorders associated with induced complement activity. In preferred embodiments, the present invention more particularly relates to methods and materials for the treatment and diagnosis of ocular disorders, including, but not limited to, the treatment and diagnosis of C5-mediated disor...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K48/00
Inventor D·爱泼斯坦J·C·库尔兹
Owner ARCHEMIX CORP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com